Compare Stocks: SDGR, EWTX, ACAD, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.61 -1.0%	$23.83	$19.69 ▼ $28.35	$4.43B	0.81	1.41 million shs	1.37 million shs
EWTX Edgewise Therapeutics	$38.38 -0.1%	$38.59	$12.30 ▼ $48.40	$4.13B	0.3	1.01 million shs	767,590 shs
LEGN Legend Biotech	$19.01 +2.5%	$27.77	$16.24 ▼ $39.16	$3.45B	0.37	2.64 million shs	2.04 million shs
SDGR Schrodinger	$15.28 +0.9%	$15.44	$10.94 ▼ $23.02	$1.12B	1.63	891,304 shs	982,172 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.15%	-0.39%	+17.86%	+9.94%
EWTX Edgewise Therapeutics	0.00%	-5.90%	-2.86%	+25.55%	+168.55%
LEGN Legend Biotech	0.00%	-16.52%	-37.98%	-21.36%	-52.19%
SDGR Schrodinger	0.00%	+1.14%	-10.31%	+22.20%	-22.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.61 -1.0%	$23.83	$19.69 ▼ $28.35	$4.43B	0.81	1.41 million shs	1.37 million shs
EWTX Edgewise Therapeutics	$38.38 -0.1%	$38.59	$12.30 ▼ $48.40	$4.13B	0.3	1.01 million shs	767,590 shs
LEGN Legend Biotech	$19.01 +2.5%	$27.77	$16.24 ▼ $39.16	$3.45B	0.37	2.64 million shs	2.04 million shs
SDGR Schrodinger	$15.28 +0.9%	$15.44	$10.94 ▼ $23.02	$1.12B	1.63	891,304 shs	982,172 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.15%	-0.39%	+17.86%	+9.94%
EWTX Edgewise Therapeutics	0.00%	-5.90%	-2.86%	+25.55%	+168.55%
LEGN Legend Biotech	0.00%	-16.52%	-37.98%	-21.36%	-52.19%
SDGR Schrodinger	0.00%	+1.14%	-10.31%	+22.20%	-22.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.67	Moderate Buy	$32.31	26.14% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$48.75	27.02% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$55.29	190.82% Upside
SDGR Schrodinger	2.33	Hold	$20.25	32.53% Upside

Current Analyst Ratings Breakdown

Latest SDGR, EWTX, ACAD, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.50
7/28/2026	LEGN Legend Biotech	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/27/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$49.00 ➝ $28.00
7/27/2026	LEGN Legend Biotech	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
7/27/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$63.00 ➝ $59.00
7/24/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$49.00 ➝ $28.00
7/21/2026	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$34.00 ➝ $36.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.09	$0.88 per share	29.16	$7.25 per share	3.53
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
LEGN Legend Biotech	$1.14B	3.10	N/A	N/A	$5.43 per share	3.50
SDGR Schrodinger	$254.91M	4.43	N/A	N/A	$4.94 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.20	11.64	26.68	17.94	34.30%	9.61%	7.07%	8/4/2026 (Confirmed)
EWTX Edgewise Therapeutics	-$167.79M	-$1.66	N/A	N/A	N/A	N/A	-32.55%	-31.04%	8/6/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	12.19	N/A	-21.98%	-24.92%	-14.87%	8/11/2026 (Estimated)
SDGR Schrodinger	-$103.26M	-$1.41	N/A	N/A	N/A	-40.61%	-30.85%	-15.32%	8/5/2026 (Estimated)

Latest SDGR, EWTX, ACAD, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.0563	N/A	N/A	N/A	$355.96 million	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	N/A	N/A	N/A	$47.19 million	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0581	N/A	N/A	N/A	$295.51 million	N/A
5/13/2026	Q1 2026	LEGN Legend Biotech	-$0.02	-$0.03	-$0.01	-$0.30	$306.51 million	$305.10 million
5/7/2026	Q1 2026	EWTX Edgewise Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	N/A	N/A
5/6/2026	Q1 2026	ACAD ACADIA Pharmaceuticals	$0.04	$0.02	-$0.02	$0.02	$280.25 million	$268.10 million
5/5/2026	Q1 2026	SDGR Schrodinger	-$0.56	-$0.81	-$0.25	-$0.81	$47.57 million	$58.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.59	3.48
EWTX Edgewise Therapeutics	N/A	22.61	22.61
LEGN Legend Biotech	N/A	2.13	2.05
SDGR Schrodinger	N/A	2.74	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
EWTX Edgewise Therapeutics	N/A
LEGN Legend Biotech	70.89%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
EWTX Edgewise Therapeutics	21.30%
LEGN Legend Biotech	0.02%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	171.24 million	126.37 million	Optionable
EWTX Edgewise Therapeutics	60	107.59 million	84.68 million	Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
SDGR Schrodinger	790	73.83 million	66.37 million	Optionable

SDGR, EWTX, ACAD, and LEGN Headlines

Recent News About These Companies

Schrodinger, Inc. $SDGR Shares Sold by Lazard Asset Management LLC

August 3 at 5:03 AM | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives Consensus Rating of "Hold" from Analysts

July 31 at 2:44 AM | americanbankingnews.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of "Hold" from Analysts

July 31 at 2:43 AM | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Schrodinger, Inc. $SDGR

July 30, 2026 | marketbeat.com

Schrodinger (SDGR) to Post Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Rubric Capital Management LP Purchases 1,828,502 Shares of Schrodinger, Inc. $SDGR

July 28, 2026 | marketbeat.com

Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery

July 27, 2026 | businesswire.com

Schrödinger to Announce Second Quarter 2026 Financial Results on August 5

July 22, 2026 | businesswire.com

Schrodinger, Inc. $SDGR Shares Purchased by Amova Asset Management Americas Inc.

July 21, 2026 | marketbeat.com

Sumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Schrodinger, Inc. $SDGR

July 14, 2026 | marketbeat.com

Schrödinger: Surviving, If Not Thriving, In The Tricky AI Drug Discovery Field

July 8, 2026 | seekingalpha.com

A Look at Schrodinger Inc (SDGR) After 6.6% Decline -- GF Value $26.32 vs Price $16.25

June 30, 2026 | gurufocus.com

What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?

June 23, 2026 | finance.yahoo.com

A Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26.55 vs Price $14.15

May 28, 2026 | gurufocus.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 22, 2026 | businesswire.com

Schrödinger Balances Growth and Losses in Earnings Call

May 20, 2026 | tipranks.com

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

May 18, 2026 | 247wallst.com

SchrÃ¶dinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 13, 2026 | seekingalpha.com

Earnings Update: Schrödinger, Inc. (NASDAQ:SDGR) Just Reported And Analysts Are Trimming Their Forecasts

May 8, 2026 | finance.yahoo.com

Schrödinger (SDGR) Q1 2026 Earnings Transcript

May 6, 2026 | finance.yahoo.com

A Look At Schrödinger (NasdaqGS:SDGR) Valuation After Q1 Earnings And Hosted AI Software Push

May 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR, EWTX, ACAD, and LEGN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.61 -0.26 (-1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$25.50 -0.11 (-0.43%)

As of 07:34 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Edgewise Therapeutics NASDAQ:EWTX

$38.38 -0.05 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$41.06 +2.69 (+7.00%)

As of 07:58 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Legend Biotech NASDAQ:LEGN

$19.01 +0.46 (+2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$19.05 +0.04 (+0.22%)

As of 07:34 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Schrodinger NASDAQ:SDGR

$15.28 +0.14 (+0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$15.32 +0.04 (+0.23%)

As of 07:34 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDGR, EWTX, ACAD, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDGR, EWTX, ACAD, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDGR, EWTX, ACAD, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR, EWTX, ACAD, and LEGN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Edgewise Therapeutics NASDAQ:EWTX

Legend Biotech NASDAQ:LEGN

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDGR, EWTX, ACAD, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDGR, EWTX, ACAD, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDGR, EWTX, ACAD, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR, EWTX, ACAD, and LEGN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Edgewise Therapeutics NASDAQ:EWTX

Legend Biotech NASDAQ:LEGN

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools